15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $65M | -$13M | 5.7% | -57.6% | -$37M | $493M | $43M |
| 2024 | $51M | -$42M | -21.1% | -142.1% | -$75M | $511M | $30M |
| 2023 | $73M | -$42M | -14.7% | -88.9% | -$55M | $428M | $8M |
| 2022 | $65M | -$71M | -33.9% | -116.6% | -$64M | $433M | $23M |
| 2021 | $70M | -$43M | -12.8% | -103.4% | -$100M | $389M | $25M |
| 2020 | $26M | -$48M | 7.7% | -185.8% | -$61M | $324M | $51M |
| 2019 | $20M | -$44M | -11.3% | -312.8% | -$61M | $233M | $11M |
| 2018 | $28M | -$34M | 10.4% | -156.8% | -$30M | $136M | $59M |
| 2017 | — | -$44M | — | — | -$10M | $153M | — |
| 2016 | — | -$38M | — | — | — | $124M | — |
| 2015 | — | -$12M | — | — | -$34M | $184M | — |
| 2014 | — | $20M | — | — | $71M | $146M | — |
| 2013 | — | $14M | — | — | $30M | $179M | — |
| 2012 | — | $21M | — | — | $31M | $141M | — |
| 2011 | — | -$34M | — | — | $19M | $32M | — |
How the market has priced CCM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Concord Medical Services Holdings Ltd's revenue has grown 20.0% per year. These are computed facts, not advice.
As of FY2025, Concord Medical Services Holdings Ltd reported $493M of total debt against $43M of cash; operating income covered interest expense -1.7×.
In FY2025, gross margin was 5.7%, operating margin -57.6%, and net margin -20.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.